Pioneering a new field of computational pharmacophenomics to unlock the life-saving potential of existing medicines.

David C Fajgenbaum, Sally Nijim, Grant Mitchell, Matej Macak, Chris Bizon, Alexander Tropsha, David Koslicki

Abstract read

In one paragraph

Article in The Lancet. Haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it

0cells of the map it votes in

4citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

Eras of bioinformatics technologies from command-line interfaces to artificial intelligence (AI) chatbots.Briefings in bioinformatics · 2026
Review
Quantify unmet medical need across the disease landscape - A large language model-based methodology.PLoS medicine · 2026
Article
Medicines, Diseases, Indications, and Contraindications (MeDIC): a foundational resource to support drug repurposing.Nucleic acids research · 2026
Article
Machine Learning-Guided Repositioning of a SARS-CoV-2-Targeting Molecular Series as Cruzain Inhibitors.ChemMedChem · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

David C FajgenbaumDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Every Cure, New York, NY, USA. Electronic address: davidfa@pennmedicine.upenn.edu.

Sally NijimDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Every Cure, New York, NY, USA.

Grant MitchellEvery Cure, New York, NY, USA.

Matej MacakEvery Cure, New York, NY, USA.

Chris BizonRenaissance Computing Institute, University of North Carolina, Chapel Hill, NC, USA.

Alexander TropshaRenaissance Computing Institute, University of North Carolina, Chapel Hill, NC, USA.

David KoslickiDepartment of Computer Science and Engineering, Biology, and The Huck Institute of the Life Sciences, Pennsylvania State University, State College, PA, USA.

Funding

mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic TargetR01HL141408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Taku Kambayashi · 2018 to 2026

$6.1M

FDA HHS R01 FD007632NHLBI NIH HHS R01 HL141408

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39909662

DOI10.1016/S2352-3026(24)00278-3

PMCPMC12090018

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.